These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 2153508)

  • 1. Cytomegalovirus seronegative heart transplant recipients. Prophylactic use of anti-CMV immunoglobulin.
    Metselaar HJ; Balk AH; Mochtar B; Rothbarth PH; Weimar W
    Chest; 1990 Feb; 97(2):396-9. PubMed ID: 2153508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Passive immunization against cytomegalovirus in allograft recipients. The Rotterdam Heart Transplant Program experience.
    Balk AH; Weimar W; Rothbarth PH; Meeter K; Metselaar HJ; Mochtar B; Simoons ML
    Infection; 1993; 21(4):195-200. PubMed ID: 8225620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group.
    Ruutu T; Ljungman P; Brinch L; Lenhoff S; Lönnqvist B; Ringdén O; Ruutu P; Volin L; Albrechtsen D; Sallerfors B; Ebeling F; Myllylä G
    Bone Marrow Transplant; 1997 Feb; 19(3):233-6. PubMed ID: 9028551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term results of CMV hyperimmune globulin prophylaxis in 377 heart transplant recipients.
    Kocher AA; Bonaros N; Dunkler D; Ehrlich M; Schlechta B; Zweytick B; Grimm M; Zuckermann A; Wolner E; Laufer G
    J Heart Lung Transplant; 2003 Mar; 22(3):250-7. PubMed ID: 12633691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of cytomegalovirus-related death by passive immunization. A double-blind placebo-controlled study in kidney transplant recipients treated for rejection.
    Metselaar HJ; Rothbarth PH; Brouwer RM; Wenting GJ; Jeekel J; Weimar W
    Transplantation; 1989 Aug; 48(2):264-6. PubMed ID: 2547256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus infections in heart and heart-lung transplant recipients.
    Wreghitt T
    J Antimicrob Chemother; 1989 Jun; 23 Suppl E():49-60. PubMed ID: 2550412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune donors can protect marrow-transplant recipients from severe cytomegalovirus infections.
    Grob JP; Grundy JE; Prentice HG; Griffiths PD; Hoffbrand AV; Hughes MD; Tate T; Wimperis JZ; Brenner MK
    Lancet; 1987 Apr; 1(8536):774-6. PubMed ID: 2882184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients.
    Snydman DR; Werner BG; Heinze-Lacey B; Berardi VP; Tilney NL; Kirkman RL; Milford EL; Cho SI; Bush HL; Levey AS
    N Engl J Med; 1987 Oct; 317(17):1049-54. PubMed ID: 2821397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
    Lowance D; Neumayer HH; Legendre CM; Squifflet JP; Kovarik J; Brennan PJ; Norman D; Mendez R; Keating MR; Coggon GL; Crisp A; Lee IC
    N Engl J Med; 1999 May; 340(19):1462-70. PubMed ID: 10320384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients.
    Vrtovec B; Thomas CD; Radovancevic R; Frazier OH; Radovancevic B
    J Heart Lung Transplant; 2004 Apr; 23(4):461-5. PubMed ID: 15063406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of combination cytomegalovirus immune globulin plus ganciclovir for prophylaxis in CMV-seronegative liver transplant recipients of a CMV-seropositive donor organ: a multicenter, open-label study.
    Snydman DR; Falagas ME; Avery R; Perlino C; Ruthazer R; Freeman R; Rohrer R; Fairchild R; O'Rourke E; Hibberd P; Werner BG
    Transplant Proc; 2001 Jun; 33(4):2571-5. PubMed ID: 11406251
    [No Abstract]   [Full Text] [Related]  

  • 12. Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients.
    Winston DJ; Ho WG; Bartoni K; Champlin RE
    Bone Marrow Transplant; 1993 Sep; 12(3):283-8. PubMed ID: 8241988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of cytomegalovirus (CMV) hyperimmune globulin for prevention of CMV disease in CMV-seropositive lung transplant recipients.
    Zamora MR; Fullerton DA; Campbell DN; Leone S; Diercks MJ; Fisher JH; Badesch DB; Grover FL
    Transplant Proc; 1994 Oct; 26(5 Suppl 1):49-51. PubMed ID: 7940974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of cytomegalovirus antibody negative patients undergoing heart transplantation.
    Freeman R; Gould FK; McMaster A
    J Clin Pathol; 1990 May; 43(5):373-6. PubMed ID: 2164531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Which renal transplant patients should receive cytomegalovirus immune globulin? A cost-effectiveness analysis.
    Tsevat J; Snydman DR; Pauker SG; Durand-Zaleski I; Werner BG; Levey AS
    Transplantation; 1991 Aug; 52(2):259-65. PubMed ID: 1651575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent occult infection with Cytomegalovirus in cardiac transplant recipients despite antiviral prophylaxis.
    Potena L; Holweg CT; Vana ML; Bashyam L; Rajamani J; McCormick AL; Cooke JP; Valantine HA; Mocarski ES
    J Clin Microbiol; 2007 Jun; 45(6):1804-10. PubMed ID: 17409205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients.
    Abate D; Saldan A; Fiscon M; Cofano S; Paciolla A; Furian L; Ekser B; Biasolo MA; Cusinato R; Mengoli C; Bonfante L; Rossi B; Rigotti P; Sgarabotto D; Barzon L; Palù G
    J Infect Dis; 2010 Aug; 202(4):585-94. PubMed ID: 20594105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Failure of prophylactic ganciclovir to prevent cytomegalovirus disease in recipients of lung transplants.
    Bailey TC; Trulock EP; Ettinger NA; Storch GA; Cooper JD; Powderly WG
    J Infect Dis; 1992 Mar; 165(3):548-52. PubMed ID: 1311352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CMV infections in bone marrow transplanted patients--evaluation of prophylaxis with Cytotect (CMV hyperimmuneglobulin).
    Zintl F; Färber I; Hermann J; Fuchs D; Prager J; Wutzler P
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(3-4):557-64. PubMed ID: 2480308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies evaluating high-dose acyclovir, intravenous immune globulin, and cytomegalovirus hyperimmunoglobulin for prophylaxis against cytomegalovirus in kidney transplant recipients.
    Dickinson BI; Gora-Harper ML; McCraney SA; Gosland M
    Ann Pharmacother; 1996 Dec; 30(12):1452-64. PubMed ID: 8968459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.